Comparing anakinra and tocilizumab for NORSE seizures
Treatments studied
Part of Brain & nervous system clinical trials.
This trial compares two medicines, anakinra and tocilizumab, to see which works better for people with hard-to-stop seizures (called NORSE) that start suddenly. It may be an option for those who don't have other serious health conditions and whose seizures began within the past week.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or the patient must be 2 years old or older.
- Seizures must not have stopped after two different seizure medicines (refractory status epilepticus), and the cause was not found in the first 3 days.
- Before these seizures, the patient had no active epilepsy or other major brain disorder.
- The patient cannot have a serious medical illness like spreading cancer, kidney failure, liver failure, or poorly controlled diabetes.
- For the main treatment part, the seizures must have started within the last 7 days, and the doctors must be thinking about using anakinra or tocilizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
This trial tests a new cell therapy (NRTX-1001) for people with epilepsy that starts in both sides of the brain's temporal lobes and doesn't get better with medication. It aims to reduce or stop seizures.
This trial tests if ketamine can help stop seizures that haven't responded to standard medicines. It is for adults whose seizures continue after two or more emergency treatments.
This study is looking at how well a procedure called SEEG thermocoagulation (a way to stop seizures by heating a small area of brain tissue) works for people with epilepsy that doesn't improve with medication. By joining, you will help doctors understand why this treatment works for some people and not others.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This study compares two ways to stop non-convulsive seizures in the ICU. It tests whether fast sedation in intensive care works better than giving higher-dose anti-seizure medicine through a vein.
Hear when a new New Onset Refractory Status Epilepticus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.